Pilot Study of Neoantigen Peptides and Leukine for the Treatment of Neoplasms
Early Phase 1
Recruiting
- Conditions
- Neoplasms
- Interventions
- Biological: Neoantigen Peptides
- First Posted Date
- 2022-07-26
- Last Posted Date
- 2024-03-06
- Lead Sponsor
- Instituto de Medicina Regenerativa
- Target Recruit Count
- 100
- Registration Number
- NCT05475106
- Locations
- π²π½
Instituto de Medicina Regenerativa, Tijuana, Baja California, Mexico
Pilot Study of Neoantigen Peptides for the Treatment of Neoplasms
Early Phase 1
Completed
- Conditions
- Neoplasms
- Interventions
- Biological: Neoantigen Peptides
- First Posted Date
- 2020-08-11
- Last Posted Date
- 2024-03-06
- Lead Sponsor
- Instituto de Medicina Regenerativa
- Target Recruit Count
- 30
- Registration Number
- NCT04509167
- Locations
- π²π½
Instituto de Medicina Regenerativa, Tijuana, Baja California, Mexico
Use of Mesenchymal Stem Cells in Acute Respiratory Distress Syndrome Caused by COVID-19
Early Phase 1
Active, not recruiting
- Conditions
- ARDS, HumanCovid-19
- Interventions
- Biological: Mesenchymal Stem Cells derived from Wharton Jelly of Umbilical cords
- First Posted Date
- 2020-07-02
- Last Posted Date
- 2024-03-06
- Lead Sponsor
- Instituto de Medicina Regenerativa
- Target Recruit Count
- 9
- Registration Number
- NCT04456361
- Locations
- π²π½
Instituto de Medicina Regenerativa, Tijuana, Baja California, Mexico
Β© Copyright 2025. All Rights Reserved by MedPath